Collegium Pharmaceutical (COLL) Price to Earnings (2015 - 2026)

Collegium Pharmaceutical has reported Price to Earnings for 12 years, with the latest figure at 78.16 in Q2 2026.

• On a quarterly basis, Price to Earnings fell 200.4% year-over-year to 78.16 in Q2 2026; TTM through Jun 2026 was 24.55, a 4.54% decrease from a year earlier, with the FY2025 full-year figure at 23.35, up 79.36% from the prior year.
• Price to Earnings was 78.16 for Q2 2026 at Collegium Pharmaceutical, down from 73.93 in the prior quarter.
• The five-year high for Price to Earnings was 1183.98 in Q3 2022, with the low at 116.44 in Q2 2022.
• Average Price to Earnings over 5 years is 104.34, with a median of 49.45 recorded in 2024.
• The largest YoY upside for Price to Earnings was 1286.86% in 2022 against a maximum downside of 1126.18% in 2022.
• Over 5 years, Price to Earnings stood at 109.08 in 2022, then jumped by 128.15% to 30.71 in 2023, then soared by 133.97% to 71.85 in 2024, then advanced by 20.45% to 86.54 in 2025, then tumbled by 190.32% to 78.16 in 2026.
• The last three Price to Earnings figures came in at 78.16 (Q2 2026), 73.93 (Q1 2026), and 86.54 (Q4 2025), per Business Quant data.